Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer
Restricted accessEditorialFirst published online January, 2026
Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer
LawrenceEO, LivingstonMS. The evolution of the cyclotron. Phys Rev, 1932; 40(1):19–35.
2.
BeierwaltesWH. The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med, 1978; 8(1):79–94; doi: 10.1016/s0001-2998(78)80009-9
3.
DaiG, LevyO, CarrascoN. Cloning and characterization of the thyroid iodide transporter. Nature, 1996; 379(6564):458–460; doi: 10.1038/379458a0
4.
FujiwaraT, KofujiN, KishimotoY, et al.Are total thyroidectomy and adjuvant radioactive iodine treatment required in all patients with N1b intermediate-high risk papillary thyroid carcinoma? Thyroid, 2026; 36(1):36–45; doi: 10.1177/10507256251401241
5.
RingelMD, SosaJA, BalochZ, et al.2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025; 35(8):841–985.
6.
RosarioPW, MourãoGF, CalsolariMR. Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine? Endocrine, 2020; 70(3):552–557; doi: 10.1007/s12020-020-02414-1
7.
RuelE, ThomasS, DinanM, et al.Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab, 2015; 100(4):1529–1536; doi: 10.1210/jc.2014-4332
8.
ChowSM, YauS, KwanCK, et al.Local and regional control in patients with papillary thyroid carcinoma: Specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer, 2006; 13(4):1159–1172; doi: 10.1677/erc.1.01320
9.
SpitzwegC, HarringtonKJ, PinkeLA, et al.Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab, 2001; 86(7):3327–3335; doi: 10.1210/jcem.86.7.7641
10.
NilssonJN, SiikanenJ, CondelloV, et al.Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up. Eur Thyroid J, 2023; 12(4):e230099; doi: 10.1530/ETJ-23-0099
